• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 15, 2019

View Archived Issues

Biopharma sector has no difficulty in attracting capital during the year

Despite a rough ride on the capital markets, particularly in the second half of the year, the biopharmaceutical sector had no difficulty in attracting capital. According to BioWorld data, the $67.1 billion that was raised by global companies from public and private sources in 2018 was just shy of the leading total of $68.4 billion generated in 2015 and places it firmly in second place in terms of totals raised in the history of the industry. Read More

FDA sustains recalls, routine inspections as shutdown drags on

The U.S. federal government shutdown is well into its fourth week, and the FDA budget is still taking a substantial hit as the White House and House Democrats wrangle over immigration policy. FDA Commissioner Scott Gottlieb has taken to Twitter frequently in recent days, stating that while a number of functions have ground to a halt, the agency will focus on safety and thus continue its work on drug and device recalls and routine inspections, the latter of which has been expanded beyond the for-cause inspections initially announced by the agency. Read More

Verona touts effects of COPD drug ensifentrine despite phase II primary endpoint miss

LONDON – Verona Pharma plc published data showing its dual action bronchodilator, ensifentrine (RPL-554), can provide additional benefits for chronic obstructive pulmonary disorder (COPD) patients who are considered to be achieving maximum bronchodilation from existing dual or triple therapies. Read More

Korean firms Bridge, Daewoong ink deal for Pellino-1 inhibitor

HONG KONG – South Korean pharmaceutical companies Bridge Biotherapeutics Inc. and Daewoong Pharmaceutical Co. Ltd. have forged a partnership to develop a drug candidate targeting pellino proteins for treating ulcerative colitis (UC). Read More

Researchers find new 'Angle' for targeting CTC clusters, plan trial using companion Dx

LONDON – Swiss researchers have uncovered a potential new route to preventing metastasis, after succeeding in harvesting intact circulating tumor cell (CTC) clusters that are the precursors of metastases, from the blood of breast cancer patients. Read More

New Zealand prepares major overhaul of drug, device regs

PERTH, Australia – After nearly 40 years, New Zealand is preparing new legislation to regulate drugs and devices that would replace the Medicines Act 1981. Read More

Narrow road may lead Evenity to U.S. osteoporosis market

The road to the U.S. market may be opening up for Amgen Inc.'s Evenity (romosozumab), an osteoporosis candidate that received a complete response letter in 2017 after it unexpectedly raised cardiovascular concerns in a pivotal trial. Read More

Financings

Mesoblast Ltd, of Melbourne, Australia, has drawn down a further $15 million from its $75 million four-year credit facility with Hercules Capital Inc. It said the funds will be used primarily to ramp up its commercialization programs, including building out a targeted sales force for remestemcel-L, an experimental therapy for acute graft-vs.-host disease for which Mesoblast plans to soon submit a rolling biologics license application to the FDA. Read More

Other news to note

Rogcon Biosciences Inc., of New Haven, Conn., partnered with Prometheus Research to support the creation of a clinical data registry to assist a planned international natural history study of patients with SCN2A mutations, which Rogcon said are the most common cause of neurodevelopmental disease including epilepsy and autism. Read More

Regulatory front

The EMA issued a revised guideline Monday on evaluating antibacterial drugs to better align data requirements for clinical trials. The revision reflects extensive discussions among regulators in the EU, Japan and the U.S. to help sponsors of the drugs design clinical trials that meet the evidence needs of multiple regulatory agencies.                                             Read More

Clinical data for Jan. 14, 2019

Read More

Regulatory actions for Jan. 14, 2019

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 7, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 7, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe